The sustained 3-year efficacy and safety data significantly de-risks this gene therapy candidate. Traders should monitor for progression to later-stage trials and potential partnerships. The commercial projections, while speculative, indicate substantial market opportunity if the therapy gains approval.
Price Chart
Executive Summary
MeiraGTx announced positive 3-year durability data from its Phase 1 AQUAx clinical trial of AAV-hAQP1 for radiation-induced xerostomia, showing sustained symptom and saliva flow improvements. The company also provided forward-looking commercial projections estimating up to $3.7 billion in peak global revenue.
Key Facts
- 3-year data from Phase 1 AQUAx trial shows sustained improvements in xerostomia symptoms and unstimulated whole saliva flow rate
- 62% of participants maintained at least a 10-point improvement in Xerostomia Questionnaire score at 36 months
- Unstimulated Whole Saliva Flow Rate normalized to 0.34 mL/min at 36 months, within normal range
- AAV-hAQP1 was safe and well-tolerated with no dose-limiting toxicity or treatment-related serious adverse events
- Company estimates peak global annual revenue potential of $3.7 billion, with $3.2 billion steady state in late 2030s
Financial Impact
Estimated peak global revenue potential of $3.7 billion with $2.0 billion in U.S. alone, though these are forward-looking projections based on market research
Risk Factors
- Forward-looking revenue estimates are speculative and subject to numerous risks including regulatory approval, market adoption, and competition
- Phase 1 data from a small cohort may not predict outcomes in larger, more diverse populations
- Clinical development risks including potential safety issues in larger trials or failure to demonstrate efficacy
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-044025 |
| Document: mgtx-20260416xex99d1.htm | 0001104659-26-044025 |
| Document: 0001104659-26-044025-index-headers.html | 0001104659-26-044025 |
| Document: 0001104659-26-044025-index.html | 0001104659-26-044025 |
| Document: 0001104659-26-044025.txt | 0001104659-26-044025 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 144 | $10.82 | awaiting T+60 | — | $9.52 (−12.01%) |
Sep 24, 2026 4w ago | 3 | $10.91 | awaiting T+60 | — | $9.52 (−12.74%) |
Sep 23, 2026 4w ago | 8-K | $11.75 | awaiting T+60 | — | $9.52 (−18.98%) |
Aug 18, 2026 9w ago | 144 | $14.97 | awaiting T+60 | — | $9.52 (−36.41%) |
Aug 13, 2026 10w ago | 8-K | $12.67 | awaiting T+60 | — | $9.52 (−24.86%) |
Aug 13, 2026 10w ago | Press Release | $12.67 | awaiting T+60 | — | $9.52 (−24.86%) |
Jul 7, 2026 16w ago | 8-K | $14.66 $11.00 | ▼ −24.97% | ▼ −26.96% | $9.52 (−35.06%) |
May 19, 2026 22w ago | 144 | $9.58 $13.52 | ▲ +41.13% | ▲ +36.12% | $9.52 (−0.63%) |
May 14, 2026 23w ago | 8-K | $9.95 $13.02 | ▲ +30.85% | ▲ +27.27% | $9.52 (−4.32%) |
May 14, 2026 23w ago | Press Release | $9.95 $13.02 | ▲ +30.85% | ▲ +27.27% | $9.52 (−4.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers